4.8 Article

Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal

Journal

CELL
Volume 173, Issue 3, Pages 581-+

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2018.03.057

Keywords

-

Funding

  1. Cancer Research UK (CRUK) [C50947/A18176]
  2. NIH Research (NIHR) Biomedical Research Centre (BRC) at the Royal Marsden Hospital [A109]
  3. NIH Research (NIHR) Biomedical Research Centre (BRC) at the Institute of Cancer Research [A109]
  4. Ministerio de Economia y Competitividad (MINECO) [SAF2016-79847-R]
  5. Royal Marsden Cancer Charity
  6. UK Medical Research Council [MR/P014712/1, FC001202]
  7. CRUK
  8. Rosetrees
  9. NIHR BRC at University College London Hospitals
  10. Cancer Research UK (TRACERx)
  11. Cancer Research UK (CRUK Cancer Immunotherapy Catalyst Network)
  12. CRUK Lung Cancer Centre of Excellence
  13. Stand Up 2 Cancer (SU2C)
  14. Rosetrees Trust
  15. Stoneygate Trust
  16. NovoNordisk Foundation [16584]
  17. Breast Cancer Research Foundation (BCRF)
  18. European Research Council (THESEUS)
  19. Marie Curie Network PloidyNet
  20. CRUK University College London Experimental Cancer Medicine Centre
  21. Cancer Research UK [C50947/A18176, FC001202]
  22. Ventana Medical Systems [10467, 10530]
  23. Kidney Cancer Fund of The Royal Marsden Cancer Charity
  24. NIHR BRC at the Royal Marsden Hospital [A109]
  25. NIHR BRC at the Institute of Cancer Research [A109]
  26. Francis Crick Institute
  27. Wellcome Trust [FC001202]
  28. Advanced Sequencing Facility at the Francis Crick Institute
  29. High-Performance Computing at the Francis Crick Institute
  30. Medical Research Council [MR/L016311/1]
  31. Medical Research Council [MR/L016311/1] Funding Source: researchfish
  32. MRC [MR/P014712/1, MR/L016311/1] Funding Source: UKRI

Ask authors/readers for more resources

Clear-cell renal cell carcinoma (ccRCC) exhibits a broad range of metastatic phenotypes that have not been systematically studied to date. Here, we analyzed 575 primary and 335 metastatic biopsies across 100 patients with metastatic ccRCC, including two cases sampledat post-mortem. Metastatic competence was afforded by chromosome complexity, and we identify 9p loss as a highly selected event driving metastasis and ccRCC-related mortality (p = 0.0014). Distinct patterns of metastatic dissemination were observed, including rapid progression to multiple tissue sites seeded by primary tumors of monoclonal structure. By contrast, we observed attenuated progression in cases characterized by high primary tumor heterogeneity, with metastatic competence acquired gradually and initial progression to solitary metastasis. Finally, we observed early divergence of primitive ancestral clones and protracted latency of up to two decades as a feature of pancreatic metastases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available